USPTO serial 87765139
EBI EXPONENTIAL BIOTHERAPIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 29, 2022
- Examiner
- INGRAM, KYLE G
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EBI EXPONENTIAL BIOTHERAPIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
HOPE V. SHOVEIN
HOPE V. SHOVEIN BROOKS KUSHMAN, P.C.1000 TOWN CENTER, 22ND FLOORSOUTHFIELD, MI 48075UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | medicines, namely, medicines for alleviating or treating vasculogenic disease, medicines for alleviating or treating hemodynamic instabilities, medicines for alleviating or treating diabetes, medicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugs, namely, pharmaceutical preparations for alleviating or treating vasculogenic disease, pharmaceutical preparations alleviating or treating hemodynamic instabilities, pharmaceutical preparations for alleviating or treating diabetes, pharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugs, namely, biopharmaceutical preparations for alleviating or treating vasculogenic disease, biopharmaceutical preparations for alleviating or treating hemodynamic instabilities, biopharmaceutical preparations for alleviating or treating diabetes, biopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticals, namely, biopharmaceuticals for alleviating or treating vasculogenic disease, biopharmaceuticals alleviating or treating hemodynamic instabilities, biopharmaceuticals for alleviating or treating diabetes, biopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposes, namely, synthetic peptides for alleviating or treating vasculogenic disease, synthetic peptides for alleviating or treating hemodynamic instabilities, synthetic peptides for alleviating or treating diabetes, synthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposes, namely, sytnthetic peptidomimetics for alleviating or treating vasculogenic disease, synthetic peptidomimetics for alleviating or treating hemodynamic instabilities, synthetic peptidomimetics for alleviating or treating diabetes, synthetic peptidomimetics for alleviating or treating of immune system related diseases and disorders | ACTIVE | — |
| 040 | custom manufacture of medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics; processing of medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for others | ACTIVE | — |
| 042 | biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals and pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; development, testing, and inspection of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; laboratory services relating to medicines, synthetic peptides, synthetic peptidomimetics, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals, namely, research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Exponential Biotherapies, Inc.
- Other trademarks owned by Exponential Biotherapies, Inc.
- Other trademarks owned by Exponential Biotherapies, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named EBI EXPONENTIAL BIOTHERAPIES
- Prosecution event R.PR explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 29, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 11, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 11, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 22, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 7, 2021 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 2, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 2, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 2, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 2, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 2, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 29, 2021 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 9, 2021 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 25, 2021 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 16, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 13, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 13, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 13, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 12, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 12, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 12, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 1, 2021 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 1, 2021 | PBSR | WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST | — |
| Oct 1, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 1, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 1, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 1, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 18, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 18, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 17, 2021 | ALIE | ASSIGNED TO LIE | — |
| Feb 11, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 1, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 1, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 1, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 11, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 4, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 18, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Aug 18, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Aug 18, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Aug 4, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 9, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 9, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 9, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 19, 2019 | ALIE | ASSIGNED TO LIE | — |
| Dec 16, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 15, 2019 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 15, 2019 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 15, 2019 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 11, 2019 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 20, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 20, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 20, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 10, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 9, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 9, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 2, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 8, 2018 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Feb 7, 2018 | ALIE | ASSIGNED TO LIE | — |
| Feb 3, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Feb 2, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 30, 2018 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 25, 2018 | NWAP | NEW APPLICATION ENTERED | — |